Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas

Carneiro, Ana; Bendahl, Pär‐Ola; Åkerman, Måns; Domanski, Henryk A.; Rydholm, Anders; Engellau, Jacob; Nilbert, Mef

doi:10.1136/jcp.2011.089805

Cited by 21 publications

(14 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of ezrin expression levels in tumour samples has revealed a clear association with tumour progression, metastatic spread and poor clinical outcome in several cancers, including breast cancer, malignant melanoma, ovarian carcinoma and soft tissue sarcomas [14][15][16][17]. In osteosarcoma, high ezrin expression is linked to pulmonary metastasis and a more aggressive course of disease [18].…”

Section: Introductionmentioning

confidence: 99%

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

Ługowska

Mierzejewska²,

Lenarcik³

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

Ezrin is a protein that functions as a cross-linker between actin cytoskeleton and plasma membrane. Its clinical role in osteosarcoma is unclear. The aim of this study was to investigate, in osteosarcoma, the prognostic value of ezrin expression at biopsy and changes in expression levels after preoperative chemotherapy. Thirty-eight newly diagnosed osteosarcoma patients aged 6-23 years were included. At diagnosis, 20 patients had localized disease, the others had distant metastases. Median follow-up was 75 months (range 13-135). Ezrin expression was assessed immunohistochemically in biopsy tissue and primary tumour specimens resected after chemotherapy. The influence on survival of changes in ezrin expression after chemotherapy was analysed. Ezrin expression was significantly higher after preoperative chemotherapy and changes compared to biopsy tissue were significantly lower in patients with early progression than in patients with relapse or no further evidence of disease (p = 0.006 and p = 0.002, respectively). Similarly, ezrin expression was higher after preoperative chemotherapy and exhibited less change in expression in deceased patients compared to patients surviving more than 5 years (both p = 0.001). Ezrin expression at biopsy was significantly associated with both histopathological aggressiveness (p < 0.001) and tumour size (p = 0.037). The results of this study provide evidence that changes in overexpression of ezrin due to preoperative chemotherapy could be a useful predictive and prognostic marker in patients with osteosarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

Ługowska

Mierzejewska²,

Lenarcik³

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, our study is retrospective and included only one TMA core per case. It is of note, however, that several recent studies used the same methods we have applied herein such as scoring system and TMA block 7,11,15,16. Nevetheless, the present findings remain to be confirmed by further studies.…”

Section: Discussionmentioning

confidence: 53%

“…Recently, many studies have suggested that increased ezrin expression was associated with poor outcome in various types of cancers, in various organs, including gastric carcinoma,7 colorectal carcinoma,8,9 nasopharyngeal carcinoma,10 esophageal SCC,11 breast carcinoma,12 osteosarcoma,13,14 various soft tissue sarcomas,15,16 cutaneous basal cell carcinoma and SCC,17 and melanoma 18. Some cohort studies19,21 suggested the distinct fuction of ezrin in tumor cell invasion or metastasis, however, no report to date has ever identified its favorable prognostic value.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer

Lee

Kim

2012

Korean J Pathol

View full text Add to dashboard Cite

BackgroundEzrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs).MethodsImmunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis.ResultsThe ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p=0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC.ConclusionsEzrin might be a molecular marker to predict poor prognosis of NSCLC.

show abstract

“…The total number of patients included for meta-analysis was 4693, ranging from 40 to 487 per study. In total, 22 studies had data on OS [6], [7], [8], [10], [11], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], and 7 study have data on DFS [6], [9], [23], [33], [34], [35], [36]. 13 reports originated from Asia, 14 from Non Asia.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Ezrin in Solid Tumors: A Meta-Analysis of the Literature

Han

Gan

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

PurposeEzrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.MethodsSeveral databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.ResultsTwenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60–2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0–3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.ConclusionsOur findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

show abstract

Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas

Abstract: Ezrin independently predicts development of local recurrences and metastases in soft tissue sarcomas. The possibility of preoperative evaluation makes ezrin a potential marker for identification of high-risk sarcoma patients who would benefit from neoadjuvant therapy.

Cited by 21 publications

References 49 publications

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

The clinical significance of changes in ezrin expression in osteosarcoma of children and young adults

Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer

Prognostic Value of Ezrin in Solid Tumors: A Meta-Analysis of the Literature

Contact Info

Product

Resources

About